Is extravasation a Fas-regulated process?

Molecular Medicine Today

Volumn 5, Issue 2, 1999, Pages 61-67

  Walsh, Kenneth ^a   Sata, Masataka ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ST ELIZABETH'S MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; FAS LIGAND;

ANGIOGENESIS; APOPTOSIS; ATHEROSCLEROSIS; EXTRAVASATION; GENE TRANSFER; LEUKOCYTE ACTIVATION; PROTEIN EXPRESSION; REGULATORY MECHANISM; RESTENOSIS; REVIEW; VASCULAR ENDOTHELIUM;

EID: 0033082984     PISSN: 13574310     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-4310(98)01415-4     Document Type: Note

References (63)

1. Springer T.A. Traffic signals on endothelium for lymphocyte recirculation and leukocyte emigration. Annu. Rev. Physiol. 57:1995;827-872.
2. Luscinskas F.W., Gimbrone M.A.J. Endothelial-dependent mechanism in chronic inflammatory leukocyte recruitment. Annu. Rev. Med. 47:1996;413-421.
3. Springer T.A. Traffic signals for leukocyte recirculation and leukocyte emigration: the multistep paradigm. Cell. 76:1994;301-314.
4. Arras M.et al. Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb. J. Clin. Invest. 101:1998;40-50.
5. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 362:1993;801-809.
6. Itoh N., Nagata S. A novel protein domain required for apoptosis: mutational analysis of human Fas antigen. J. Biol. Chem. 268:1993;10932-10937.
7. Boldin M.P.et al. Involvement of Mach, a novel MORT1/FADD-interacting protease, in FAS/Apo-1 and TNF receptor-induced cell death. Cell. 85:1996;803-815.
8. Muzio M.et al. FLICE, a novel, FADD-homologous ICE/CED-3-like protease is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell. 85:1996;817-827.
9. Enari M.et al. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature. 391:1998;43-50.
10. Irmler M.et al. Inhibition of death receptor signals by cellular FLIP. Nature. 388:1997;190-195.
11. Nagata S., Golstein P. The Fas death factor. Science. 267:1995;1449-1456.
12. Griffith T.S et al. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 270:1995;1189-1192.
13. Bellgrau D.et al. A role of CD95 ligand in preventing graft rejection. Nature. 377:1995;630-632.
14. Hahne M.et al. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science. 274:1996;1363-1366.
15. Strand S.et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand expressing tumor cells - A mechanism of immune evasion? Nat. Med. 2:1996;1361-1366.
16. Niehans G.A.et al. Human lung carcinomas express Fas ligand. Cancer Res. 57:1997;1007-1012.
17. Miwa K.et al. Caspase 1-independent IL-1βf release and inflammation induced by the apoptosis inducer Fas ligand. Nat. Med. 4:1998;1287-1292.
18. Sata M., Walsh K. TNFα Regulation of Fas ligand expression on the vascular endothelium modulates leukocyte extravasation. Nat. Med. 4:1998;415-420.
19. Richardson B.C.et al. Fas ligation triggers apoptosis in macrophages but not endothelial cells. Eur. J. Immunol. 24:1994;2640-2645.
20. Sata M.et al. Fas ligand gene transfer to the vessel wall inhibits neointima formation and overrides the adenovirus-mediated T cell response. Proc. Natl. Acad. Sci. U. S. A. 95:1998;1213-1217.
21. Sata M., Walsh K. Endothelial cell apoptosis induced by oxidized LDL is associated with the down-regulation of the cellular caspase inhibitor FLIP. J. Biol. Chem. 273:1998;33103-33106.
22. Sata M., Walsh K. Oxidized LDL activates Fas-mediated endothelial cell apoptosis. J. Clin. Invest. 102:1998;1682-1689.
23. Dong C.et al. Human transplant coronary artery disease: pathological evidence for Fas-mediated apoptotic cytotoxicity in allograft arteriopathy. Lab. Invest. 74:1996;921-931.
24. Geng Y.-J.et al. Fas is expressed in human atherosclerotic intima and promotes apoptosis of cytokine-primed human vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 17:1997;2200-2208.
25. Risau W. Mechanisms of angiogenesis. Nature. 386:1997;671-674.
26. Folkman J. Clinical-applications of research on angiogenesis. New Engl. J. Med. 333:1995;1757-1763.
27. Risau W. Angiogenesis is coming of age. Circ. Res. 82:1998;926-928.
28. Freeman M.R.et al. Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. Cancer Res. 55:1995;4140-4145.
29. Polverini P.J.et al. Activated macrophages induce vascular proliferation. Nature. 269:1977;804-806.
30. Frater-Schroder M.W.et al. Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc. Natl. Acad. Sci. U. S. A. 84:1987;5277-5281.
31. Rupia E.et al. Role of tumor necrosis factor-alpha and platelet-activating factor in neoangiogenesis induced by synovial fluids of patients with rheumatoid arthritis. Eur. J. Immunol. 26:1996;1690-1694.
32. Biancone L.et al. Development of inflammatory angiogenesis by local stimulation of Fas in vivo. J. Exp. Med. 186:1997;147-152.
33. Scandinavian Simvastatin Survival Study Group (1994) Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S), Lancet 344, 1383-1389.
34. Steinberg D.et al. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenesity. New Engl. J. Med. 320:1989;915-924.
35. Sawamura T.et al. An endothelial receptor for oxidized low-density lipoprotein. Nature. 386:1997;73-77.
36. Steinberg D. Low density lipoprotein oxidation and its pathological significance. J. Biol. Chem. 272:1997;20963-20966.
37. Kodama T.et al. Type I macrophage scavenger receptor contains α-helical and collagen-like coiled coils. Nature. 343:1990;531-535.
38. Ylä-Herttuala S.et al. Evidence for the presence of oxidatively modified LDL in atherosclerotic lesions of rabbit and man. J. Clin. Invest. 84:1989;1086-1095.
39. van der Wal A.C.et al. Atherosclerotic lesions in human: in situ immunophenotypic analysis suggesting an immune mediated response. Lab. Invest. 61:1989;166-170.
40. Hansson G.K., Holm J., Jonasson L. Detection of activated T lymphocytes in the human atherosclerotic plaque. Am. J. Pathol. 135:1989;169-175.
41. Stemme S., Holm J., Hansson G.K. T lymphocytes in human atherosclerotic plaques are memory cells expressing CD45RO and the integrin VLA-1. Arterioscler. Thromb. 12:1992;206-221.
42. Emeson E.E., Robertson A.L. T lymphocytes in aortic and coronary intimas: their potential role in atherogenesis. Am. J. Pathol. 130:1988;369-376.
43. Libby P., Hansson G.K. Involvement of the immune system in human atherogenesis: Current knowledge and unanswered questions. Lab. Invest. 64:1991;5-15.
44. Barath P.et al. Tumor necrosis factor gene expression in human vascular intimal smooth muscle cells detected by in situ hybridization. Am. J. Pathol. 137:1990;503-509.
45. Jonasson L.et al. Expression of class II transplantation antigen on vascular smooth muscle cells in human atherosclerosis. J. Clin. Invest. 76:1985;125-131.
46. Jonasson L.et al. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaquea. Arteriosclerosis. 6:1986;131-138.
47. Tanaka H.et al. Smooth muscle cells of the coronary arterial tunica media express tumor necrosis factor-α and proliferate during acute rejection of rabbit cardiac allografts. Am. J. Pathol. 147:1995;617-626.
48. Munro J.M.et al. An immunohistochemical analysis of human aortic fatty streaks. Hum. Pathol. 18:1987;375-380.
49. Billingham M.E. Cardiac transplant atherosclerosis. Transplant. Proc. 19:1987;19-25.
50. Ross R. Genetically modified mice as models of transplant atherosclerosis. Nat. Med. 2:1996;527-528.
51. Clausell N.et al. In vivo blockade of tumor necrosis factor-α in cholesterol-fed rabbits after cardiac transplant inhibits acute coronary artery neointimal formation. Circulation. 89:1994;2768-2779.
52. McBride W., Lange R.A., Hillis L.D. Restenosis after successful coronary angioplasty: pathophysiology and prevention. New Engl. J. Med. 318:1988;1734-1737.
53. Nobuyoshi M.et al. Restenosis after successful percutaneous transluminal coronary angioplasty: serial angiographic follow-up of 229 patients. J. Am. Coll. Cardiol. 12:1988;616-623.
54. Moreno P.R.et al. Macrophage infiltration predicts restenosis after coronary intervention in patients with unstable angina. Circulation. 94:1996;3098-3102.
55. Nobuyoshi M.et al. Restenosis after percutaneous transluminal coronary angioplasty: pathologic observations in 20 patients. J. Am. Coll. Cardiol. 17:1991;433-439.
56. Kearney M.et al. Histopathology of in-stent restenosis in patients with peripheral artery disease. Circulation. 95:1997;1998-2002.
57. Kornowski R.et al. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J. Am. Coll. Cardiol. 31:1988;224-230.
58. Yang Y.et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. U. S. A. 91:1994;4407-4411.
59. Knowles M.R.et al. A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. New Engl. J. Med. 333:1995;823-831.
60. Crystal R.G.et al. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat. Genet. 8:1994;42-51.
61. Zabner J.et al. Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. Cell. 75:1993;207-216.
62. Newman K.D.et al. Adenovirus-mediated gene transfer into normal rabbit arteries results in prolonged vascular cell activation, inflammation, and neointimal hyperplasia. J. Clin. Invest. 96:1995;2955-2965.
63. Channon K.M.et al. Acute host-mediated endothelial injury after adenoviral gene transfer in normal rabbit arteries. Impact on transgene expression and endothelial function. Circ. Res. 82:1998;1253-1262.